Table 2.
Outcomes of EUS-HGS between BD groups or non-BD groups.
| Total | BD Group | Non-BD Group | p | |
|---|---|---|---|---|
| No. of cases (%) | n = 38 | n = 17 | n = 21 | |
| Procedure time, min, median (range) | 35.5 (17–80) | 37 (19–80) | 32 (17–60) | 0.601 |
| Diameter of bile duct of puncture site, mm, median (range) | 6 (4–15) | 5.8 (4–9) | 6 (4–15) | 0.149 |
| Puncture site (%) | 0.197 | |||
| B2 | 6 (15.8%) | 1 (5.9%) | 5 (23.8%) | |
| B3 | 32 (84.2%) | 16 (94.1%) | 16 (76.2%) | |
| Initial dilation (%) | - | |||
| Balloon dilator | ||||
| REN 4 mm diameter | 14 (36.8%) | 14 (82.4%) | ||
| REN 6 mm diameter | 3 (7.9%) | 3 (17.6%) | ||
| Bougie dilator | ||||
| ES dilator (7 Fr) | 13 (34.2%) | 13 (85.7%) | ||
| Soehendra (7 Fr) | 3 (7.9%) | 3 (14.3%) | ||
| Stenting success rate after initial dilation (%) | 84.2% (32/38) | 100% (17/17) | 71.4% (15/21) | 0.024 |
| Additional dilation (%) | 6 (15.8%) | 0 | 6 (28.6%) | 0.024 |
| Balloon dilator | ||||
| REN 4 mm diameter | 4 (10.5%) | 0 | 4 (19.0%) | |
| Bougie dilator | ||||
| Soehendra (9 Fr) | 2 (5.3%) | 0 | 2 (9.5%) | |
| Adverse events (%) | ||||
| Peritonitis | 4 (10.5%) | 1 (5.9%) | 3 (14.3%) | 0.613 |
| Biloma | 1 (2.6%) | 0 | 1 (4.8%) | 1.000 |
| Bleeding | 0 | 0 | 0 | - |
| Stent migration | 0 | 0 | 0 | - |
EUS-HGS: EUS-guided hepaticogastrostomy, BD group: balloon dilation group, non-BD group: non-balloon dilation group, B2: bile duct of segment 2 of the liver, B3: bile duct of segment 3 of the liver, SEMS: self-expandable metal stent.